Q1 2025 Arrowhead Pharmaceuticals Inc Earnings Call Transcript
Key Points
- Arrowhead Pharmaceuticals Inc (ARWR) closed a significant license and collaboration agreement with Sarepta Therapeutics, expected to bring in $1.375 billion in cash payments.
- The company is now funded into 2028, with potential for multiple commercial launches by Arrowhead and its partners.
- Arrowhead Pharmaceuticals Inc (ARWR) anticipates its first commercial launch of plozasiran, which could drive substantial growth pending FDA approval.
- The company is focusing on three primary value drivers: plozasiran, obesity, and CNS, which are expected to fuel growth in the near term.
- Arrowhead Pharmaceuticals Inc (ARWR) has a robust potential catalyst calendar for 2025, with multiple key events expected throughout the year.
- Arrowhead Pharmaceuticals Inc (ARWR) reported a net loss of $173.1 million for the quarter ended December 31, 2024, compared to a net loss of $132.9 million in the previous year.
- Revenue for the quarter was $2.5 million, down from $3.6 million in the same quarter of the previous year.
- The company experienced increased operating expenses, primarily due to higher candidate costs and salaries as its pipeline of clinical candidates advanced.
- Arrowhead Pharmaceuticals Inc (ARWR) needs additional capital to start a cardiovascular outcomes trial (CVOT) for plozasiran, despite having a significant cash balance.
- The company faces challenges in expanding the market for its products, as the industry requires education and awareness to address largely untreated diseases.
Ladies and gentlemen, welcome to the Arrowhead Pharmaceuticals conference call. (Operator Instructions)
I will now hand the conference over to Vince Anzalone, Vice President of Investor Relations of Arrowhead. Please go ahead, Vince.
Good afternoon, and thank you for joining us today to discuss Arrowhead's results for its fiscal 2025 first quarter ended December 31, 2024. With us today from management, our President and CEO, Dr. Chris Anzalone, who will provide an overview of the quarter; Dr. Bruce Given, Interim Chief Medical Scientist, who will provide an update on our cardiometabolic pipeline. Andy Davis, Senior Vice President and Head of Global cardiometabolic franchise, who will provide an update on commercialization activities.
Dr. James Hamilton, Chief of Discovery and Translational Medicine, who will discuss our earlier-stage development program and Ken Myszkowski, our Chief Financial Officer, who will give a review of the financials. We will then open up the call to
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
